ATE349226T1 - Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle - Google Patents

Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Info

Publication number
ATE349226T1
ATE349226T1 AT99948942T AT99948942T ATE349226T1 AT E349226 T1 ATE349226 T1 AT E349226T1 AT 99948942 T AT99948942 T AT 99948942T AT 99948942 T AT99948942 T AT 99948942T AT E349226 T1 ATE349226 T1 AT E349226T1
Authority
AT
Austria
Prior art keywords
antiplasmin
vivo
ischemic stroke
compounds
sub
Prior art date
Application number
AT99948942T
Other languages
English (en)
Inventor
Nobuo Nagai
Desire Jose Collen
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202004A external-priority patent/EP1062953A1/de
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Application granted granted Critical
Publication of ATE349226T1 publication Critical patent/ATE349226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT99948942T 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle ATE349226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203280 1998-09-29
EP99202004A EP1062953A1 (de) 1999-06-22 1999-06-22 Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle

Publications (1)

Publication Number Publication Date
ATE349226T1 true ATE349226T1 (de) 2007-01-15

Family

ID=26150731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948942T ATE349226T1 (de) 1998-09-29 1999-09-24 Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle

Country Status (12)

Country Link
US (1) US6946438B1 (de)
EP (1) EP1117437B1 (de)
JP (1) JP4577992B2 (de)
CN (1) CN1191856C (de)
AT (1) ATE349226T1 (de)
AU (1) AU6200599A (de)
CA (1) CA2344317C (de)
DE (1) DE69934595T2 (de)
DK (1) DK1117437T3 (de)
ES (1) ES2276536T3 (de)
HK (1) HK1041449B (de)
WO (1) WO2000018436A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1343903E (pt) * 2000-12-21 2008-02-18 Thrombogenics Nv ''um vector de expressão de levedura e um método de produção de uma proteína recombinante por expressão numa célula de levedura
EP1545588A4 (de) * 2002-07-23 2007-12-05 Ludwig Inst Cancer Res Verfahren und zusammensetzungen f r die aktivierung oder hemmung von vegf-d und vegf-c
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
UA103771C2 (ru) * 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
RU2372086C1 (ru) * 2008-08-06 2009-11-10 Илья Николаевич Медведев СПОСОБ НОРМАЛИЗАЦИИ УРОВНЯ α2 АНТИПЛАЗМИНА ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2753359B1 (de) * 2011-09-06 2018-02-28 Translational Sciences Inc. Serpinf2-bindemoleküle und verfahren zu ihrer anwendung
TWI653981B (zh) * 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
EP3395354B1 (de) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen zur behandlung von diabetischer nephropathie
CN106890325A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
EP3395355B1 (de) 2015-12-18 2026-03-04 Talengen International Limited Plasminogen zur behandlung von zervixerosion
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
WO2021072404A1 (en) * 2019-10-10 2021-04-15 University Of Kentucky Research Foundation A machine learning algorithm for predicting clinical outcomes and identifying drug targets in ischemic stroke
CN117677715B (zh) * 2021-07-28 2025-09-26 北京沙东生物技术有限公司 一种骨髓瘤生物标志物serpinf2及其应用
CN114736948B (zh) * 2022-06-10 2022-11-08 深圳市帝迈生物技术有限公司 一种α2-抗纤溶酶活性测定试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis

Also Published As

Publication number Publication date
EP1117437B1 (de) 2006-12-27
HK1041449A1 (en) 2002-07-12
CN1191856C (zh) 2005-03-09
AU6200599A (en) 2000-04-17
ES2276536T3 (es) 2007-06-16
US6946438B1 (en) 2005-09-20
DE69934595T2 (de) 2007-10-04
WO2000018436A1 (en) 2000-04-06
DE69934595D1 (de) 2007-02-08
CN1320045A (zh) 2001-10-31
DK1117437T3 (da) 2007-04-10
EP1117437A1 (de) 2001-07-25
HK1041449B (zh) 2005-08-19
JP2002525340A (ja) 2002-08-13
CA2344317A1 (en) 2000-04-06
JP4577992B2 (ja) 2010-11-10
CA2344317C (en) 2012-01-24

Similar Documents

Publication Publication Date Title
DE69934595D1 (de) Verwendung von verbindungen die alpha2-antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
ATE312117T1 (de) Verbindungen für die behandlung von ischämie
TR200003011T2 (tr) Yeni dihidropirimidinler.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ITTO950002A1 (it) Trombopoietina.
BR0016058A (pt) Compostos de fosfonato
TR200001203T2 (tr) Yeni birleşik maddeler
GB9813540D0 (en) Chemical compounds
YU66000A (sh) Antipikovirusna jedinjenja, njihovo dobijanje i upotreba
NO20006645L (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
PL354030A1 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
ZA975439B (en) New pyridyl alkane acid amides.
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE60021113D1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
YU40002A (sh) Antipikornavirusna jedinjenja i kompozicije, njihove farmaceutske upotrebe, i materijali za njihove sinteze
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
FR2794977B1 (fr) Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties